WYPB: A new company with some interesting products to say the least. Kinda has a large spread over the past few weeks and moderately low volume but has some upside potential. IR person says within the next month there will be substantial news forthcoming. This company already has some of its products on the market like the drinkdetective, which is a test for date rape drugs slipped in drinks at clubs etc. and WYPB also has Homeland Security Products. Here is some DD info below.
Name: WayPoint Biomedical Holdings, Inc.
C.E.O.: Dennis Shepherd - CEO, Director
Address: 17011 Beach Blvd., Suite 792, Huntington Beach, CA. 92647
Phone: Hank Zemla, 586-228-2290 IR Firm
Fax:
Website :http://www.waypointbiomedical.com and drinkdetectiveusa.com
Email: capinc@comcast.net
Outstanding Shares: 780,000,000 Float 155,000,000
Authorized Shares: 2,000,000,000
Business Description:
WayPoint Biomedical, Inc., a wholly owned subsidiary of WayPoint Biomedical Holdings, Inc., is an innovative new biomedical firm specializing in diagnostic tests and devices for screening and monitoring human health, fitness and environment.
The Company develops and markets cutting-edge disposable rapid tests that offer both a preliminary diagnostic screen to specific conditions, along with a future path for consumers, medical providers, and first responders to follow regarding their health status or environmental condition. By providing unique, yet affordable, home-based tests, WayPoint is focused on detecting the cause of a disease or pathogen, as opposed to treating the symptom; becoming a part of the solution in helping to reverse the escalating cost of Healthcare.
The Company's primary target sectors are the Over the Counter (OTC) Self-Testing Market, the Diagnostic Point of Care (POC) Testing Market, and the Homeland Security Market; three of the fastest growing areas in all of diagnostic medicine and science
Product Overview
The Company has numerous product lines either completed or under development in the medical diagnostic and bio-defense arenas.
The Drink Detective(tm):
As WayPoint's first new product, The Drink Detective(tm) is a highly innovative rapid drink spiking test, used to detect over 60 different date rape drugs, including: Ketamine, GHB, and the Benzodiazepine drugs (e.g. Rohypnol(r) and Valium(r)). For more information please visit www.drinkdetectiveusa.com.
Homeland Security Products:
With the ever-growing global threat of terrorism, WayPoint has identified an innovative new technology for the Homeland Security and Defense market sector. First Responders must be equipped with simple and accurate detection devices that can provide clear and concise results quickly. Our planned Frontline Biological Detector Kit will address this need by rapidly screening for the presence of explosives, Ricin, Anthrax, organics, biological species, chemical warfare, and chemical pre-cursors.
Diagnostic Point of Care (POC) Products:
WayPoint's first product introductions into the POC arena will include a range of Urine Reagent Strip Tests for the semi-quantitative determination of glucose, bilirubin, protein, pH, blood, ketone, urobilinogen, nitrite, specific gravity, vitamin C and leukocytes in urine. These urine reagent strips yield clear and accurate results in as little as 30 seconds.
Over the Counter (OTC) Products:
WayPoint has identified the need to provide low-cost, at home screening tests. Our Health Essist(tm) Self-Testing product line offers sensible, cost-effective solutions to help reverse the escalating costs of health care. Our initial Health Essist(tm) product line is planned to consist of: Diabetes & Ketone Home Screening Tests, Drug-Free Center Multi-Test Kits, a Urinary Tract Infection Kit, and Alcohol Test Kits.
International Products:
A series of unique and easy-to-use, rapid tests for infectious diseases in the international POC and OTC Self-Testing markets will headline WayPoint's initial range of tests. This highly innovative, self-contained kit range includes tests for: Chlamydia, Gonorrhea, Yeast Infections (Candida), and Strep A. Additional rapid tests for Syphilis, Hepatitis, Bird Flu, Influenza A & B (w/ RSV), Malaria, Dengue Fever, TSH, Neural Disorder, and Down Syndrome will help comprise the international range.
Management Overview
The foundation of WayPoint Biomedical is a strong executive management team. With extensive industry and senior management experience, the WayPoint executive team includes Dennis Shepherd as CEO, Bret Hendzel as President and COO, and Phill Richer as the Global Director of Sales and Marketing.
Market Overview and Competitive Analysis
The global pharmaceutical and biotechnology market is estimated to be valued at $447.5 billion in 2004, growing at approximately nine percent. The Asia-Pacific and Latin America markets should grow significantly in the next 5 to 10 years and increase their presence in the global pharmaceutical landscape. While the U.S. market (estimated to contribute 41 percent of worldwide pharmaceutical sales in 2004) continues to set the pace, Europe and Japan are also major players, combining to contribute about 39 percent of global pharmaceutical sales in 2004.
With the current estimated global In Vitro Diagnostic market size at $28 billion, WayPoint intends on entering two of the most dynamic segments, the Over the Counter Self-Testing sector, and the Clinical Point of Care segment. With and estimated size of $1.5 to $2.0 billion, the OTC Self-Testing market is expected to more than double by 2007. A driving force stimulating this incredible growth is the trend toward preventative healthcare as a primary focus in medical intervention. As a result, home based self-testing is becoming an increasingly important component of preventative medicine, as individuals become more involved and aware of their health. The $3.8 billion diagnostic POC market is also experiencing rapid expansion and is projected to top $5.5 billion by 2009. WayPoint also intends to enter the rapidly expanding Homeland Security and Defense sector. The United States makes up roughly half of the expansive $180 billion global Security and Defense market segment. This industry sector is projected to nearly triple over the next ten years |
